Legend Biotech

Legend Biotech Corp. is a holding company, which engages in the discovery and development of novel cell therapies for oncology and other indications. It operates through the North America and China geographical segments. The company was founded on May 27, 2015 and is headquartered in Somerset, NJ.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Legend Biotech surpasses Q2 sales targets, eyes market expansion

Legend Biotech's Q2 performance exceeded expectations with strong sales and positive study data.
The company's financial position is robust, with a healthy cash balance and plans for capacity expansion.
While facing challenges such as competitive pressures and operational optimizations, opportunities for growth exist.
Strategic initiatives focus on product quality, market expansion, and regulatory advancements for CARVYKTI.

Legend Biotech reports robust Q3 sales, eyes profitability targets

Legend Biotech's Q3 performance reflects strong sales driven by CARVYKTI, while maintaining a solid financial position with a focus on expansion.
The company faces challenges in achieving profitability targets and providing clarity on future sales projections.
Opportunities lie in pipeline advancements, collaboration partnerships, and innovative market expansion strategies.

Legend Biotech reports robust earnings, eyes expansion and regulatory milestones

Legend Biotech's strong earnings and cash balance provide stability and growth opportunities.
CARVYKTI's efficacy and convenience position it well, with plans for capacity expansion and partnerships.
Challenges include regulatory scrutiny and the need for clarity on future manufacturing scale-up.
Opportunities lie in extending manufacturing capacity, pipeline advancements, and profitability projections by 2026.

Legend Biotech reports robust Q1 performance and accelerates CAR-T expansion

Legend Biotech's Q1 2024 showcased strong performance with significant revenue growth and expansion plans to meet rising demand.
While facing challenges like sequential sales decrease and increased expenses, the company is leveraging strengths in production capacity and market diversification.
Opportunities lie in regulatory engagements for accelerated approvals, efficient market penetration strategies, and financial flexibility for future growth.
Overall, Legend Biotech's strategic focus on CAR-T therapies positions it well for continued success and innovation in the biopharmaceutical industry.

Legend Biotech excels in Q2, eyes FDA approvals and growth

Legend Biotech's Q2 2024 performance reflects strong sales growth, regulatory milestones, and promising clinical data, positioning the company for future success.
With a solid financial position, expanded production capacity, and ongoing research initiatives, Legend Biotech demonstrates resilience and strategic foresight in a competitive market landscape.
While facing challenges such as political risks and profitability targets, the company remains focused on growth opportunities and value creation for stakeholders.

Legend Biotech excels in Q3 with CARVYKTI growth and strategic advancements

Legend Biotech's Q3 performance reflects strong sales growth, regulatory milestones, and progress in clinical trials, underpinned by a robust balance sheet and strategic leadership appointments.
While challenges in outpatient treatment adoption and trial enrollment persist, the company's focus on innovation and operational excellence presents opportunities for future growth and market leadership.
Overall, Legend Biotech's solid financial standing, coupled with its expanding product portfolio and research capabilities, positions the company favorably for continued success and value creation for stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.

Legend Biotech Corporation (NASDAQ:LEGN ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Jessie Yeung - Vice President of Investor Relations and Finance Ying Huang - Chief Executive Officer Lori Macomber - Chief Financial Officer Mythili Koneru - Chief Medical Officer Steve Gavel - Senior Vice President, Commercial Development, U.S. & Europe Conference Call Participants Gena Wang - Barclays Kelly Shi - Jefferies Jessica Fye - JPMorgan Kostas Biliouris - BMO Capital James Shin - DB Vikram Purohit - Morgan Stanley Mitchell Kapoor - H.C. Wainright Rick Bienkowski - Cantor Fitzgerald Sean McCutcheon - Raymond James Operator Ladies and gentlemen, thank you for standing by.

Legend Biotech Corporation (LEGN) Q3 2024 Earnings Call Transcript

Although the revenue and EPS for Legend Biotech (LEGN) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Legend Biotech (LEGN) Reports Q3 Earnings: What Key Metrics Have to Say

After losing some value lately, a hammer chart pattern has been formed for Legend Biotech (LEGN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Legend Biotech (LEGN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

SOMERSET, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a live webcast event for investors on Sunday, December 8, 2024, at 8:00 p.m. PT (11:00 p.m. ET) during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA.

Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of CARVYKTI to transform outcomes in refractory multiple myeloma

Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma

Newly created position to lead efforts focused on continued growth and sales Newly created position to lead efforts focused on continued growth and sales

Legend Biotech Appoints Alan Bash as President of CARVYKTI®

The mean of analysts' price targets for Legend Biotech (LEGN) points to a 90.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Legend Biotech (LEGN) Could Rally 90.83%: Here's is How to Trade

AMETEK

Carnival

CrowdStrike

Devon Energy

Eldorado Gold

Emerson Electric

Evolution AB

JFrog

Gap Inc

GRAIL Inc

Inmode Ltd

Intel

iShares U.S. Consumer Goods ETF

Johnson & Johnson

Cheniere Energy

NVIDIA

Olaplex Holdings

Ryder System

Regeneron Pharmaceuticals

In September, thirty new analysts joined Seeking Alpha, offering diverse stock picks and insights, from Strong Buy to Strong Sell ratings. Highlighted picks include InMode Ltd., Intel Corporation, and iShares 20+ Year Treasury Bond ETF, each with unique investment theses and strong buy ratings. Analysts' backgrounds range from software engineering to finance, enhancing their stock research with diverse perspectives and methodologies.

Stock Picks From Seeking Alpha's September 2024 New Analysts

Legend Biotech said on Thursday it would set up a new research and development facility in Philadelphia, Pennsylvania, to advance its portfolio of next-generation cell therapies.

Legend Biotech to set up new R&D facility in Philadelphia

New 31,000 square-foot facility will enhance Legend's leading cell therapy portfolio and expand Legend's R&D capabilities as a global cell therapy leader New 31,000 square-foot facility will enhance Legend's leading cell therapy portfolio and expand Legend's R&D capabilities as a global cell therapy leader

Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

Friday, Legend Biotech Corporation LEGN and Johnson & Johnson JNJ announced late-breaking three-year follow-up data from the Phase 3 CARTITUDE-4 study.

Johnson & Johnson/ Legend Biotech Partnered Blood Cancer Drug Extends Overall Survival, Support Use In Previously Treated Patients

SOMERSET, N.J., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced late-breaking three-year follow-up data from the Phase 3 CARTITUDE-4 study that shows a single infusion of CARVYKTI® (ciltacabtagene autoleucel) significantly extended overall survival (OS) in patients with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor (PI), and an immunomodulatory agent (IMiD), reducing the risk of death by 45 percent versus standard therapies of pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd).1 CARVYKTI® is now the first and only cell therapy to improve OS versus standard therapies for patients with lenalidomide-refractory multiple myeloma as early as second line.1 These results were presented as a late-breaking oral presentation at the 2024 International Myeloma Society (IMS) Annual Meeting (Abstract #OA-65) in Rio de Janeiro, Brazil.1

CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line

Legend Biotech said Friday its cancer drug, Carvykti, lowered the risk of death by 45% in a study of multiple myeloma patients.

Legend Biotech's J&J-Partnered Drug Cut The Risk Of Death By 45% In Multiple Myeloma

SAN FRANCISCO--(BUSINESS WIRE)-- #manufacturing--Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, today announced the launch of its collaboration with Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in the cell therapy space. This initiative will be focused on automating cell therapy manufacturing, leveraging Multiply Labs' unique approach which consists of robotic systems that can operate a wide variety of.

Multiply Labs Announces a Collaboration on Automating Cell Therapy Manufacturing with Legend Biotech

Carvykti, a CAR-T therapy co-developed by Legend Biotech & J&J, is central to second-line multiple myeloma treatment. Both firms are actively scaling up production across bases. Carvykti sales surged 60% YoY, reaching US$343 million in 1H2024, forecasting US$1 bilion+ for the full year. Rumors since July claim Legend Biotech faced a takeover bid, with fresh whispers of pricing disputes in negotiations this week.

Legend Biotech: Entering Accelerated Growth Phase, Carvykti Positions Company For Valuation Expansion

SOMERSET, N.J., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company's Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY on Wednesday, September 4, 2024, at 2:35 p.m. ET.

Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Legend Biotech Corporation (NASDAQ:LEGN ) Q2 2024 Earnings Call Transcript August 9, 2024 8:00 AM ET Company Participants Jessie Yeung - VP of IR & Finance Ying Huang - CEO Lori Macomber - CFO Steve Gavel - Head of Commercial Development for US and Europe Guowei Fang - CSO Conference Call Participants Gena Wang - Barclays Jessica Fye - JPMorgan Kelly Shi - Jefferies Ash Verma - UBS Leonid Timashev - RBC Capital Markets Jonathan Miller - Evercore ISI Yaron Werber - TD Cowen James Shin - Deutsche Bank Vikram Purohit - Morgan Stanley Justin Zelin - BTIG Mitchell Kapoor - H.C. Wainwright George Farmer - Scotiabank Rick Bienkowski - Cantor Fitzgerald Sean McCutcheon - Raymond James Asthika Goonewardene - Truist Operator Ladies and gentlemen, thank you for standing by.

Legend Biotech Corporation (LEGN) Q2 2024 Earnings Call Transcript

SOMERSET, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its second quarter 2024 unaudited financial results and key corporate highlights.

Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights

SOMERSET, N.J., July 26, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced preliminary, unaudited financial results for the six-months ended June 30, 2024.

Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024

A third-party article suggests that Legend Biotech (LEGN) hired investment banking firm Centerview Partners to help its board review the takeover offer.

Legend Biotech (LEGN) Up 12% on Reports of Takeover Bid

Legend Biotech (LEGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Legend Biotech (LEGN) Surges 12.1%: Is This an Indication of Further Gains?

SOMERSET, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Friday, August 9, 2024, to review second-quarter 2024 results.

Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results

Shares of cell therapy company Legend Biotech Corp LEGN were trading lower on Monday, after being among the top pharma gainers in the first week of June.

Legend Biotech's Cancer Drug, 'The Most Attractive Product,' Set For Growth: Analyst

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today results for the first time from the Phase 2 CARTITUDE-2 Cohort D study in multiple myeloma patients. Results showed patients with less than a complete response (CR) after front-line autologous stem cell transplant (ASCT) experienced deep and durable responses following a single infusion of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) with or without l.

Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company's Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York, NY on Thursday, June 6, 2024, at 10:30 a.m. ET. The live webcast will be available to investors and other interested parties by accessing the Investor Relations section of Legend's website. The webca.

News for Legend Biotech Stock (LEGN)